Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Stem cell- and extracellular vesicle-based therapies for perianal fistulizing Crohn's disease: An updated review

Bhatnagar P., Elhariri S., Burud IAS., Eid N.

Clinical Trial on Chronic Wound, Autoimmune Research, published in World J Gastroenterol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
World J Gastroenterol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41180780
PMCID
PMC12576588
DOI
10.3748/wjg.v31.i39.112229

Abstract (original English)

Perianal fistulizing Crohn's disease (PFCD) is a complication of CD that significantly impacts patients' quality of life, particularly their social and sexual well-being. Despite advances in therapy, its treatment remains a major challenge in the field of inflammatory bowel disease. The pathogenesis of PFCD involves increased production of inflammatory cytokines by infiltrating macrophages and lymphocytes, stimulation of the epithelial-to-mesenchymal transition, activation of myofibroblasts, and elevated levels of matrix metalloproteinases. Mesenchymal stem cells (MSCs) are multipotent stromal cells with self-renewal and differentiation capabilities. Evidence from animal models and clinical trials indicates that MSC injection into PFCD lesions suppresses the infiltration of inflammatory cells and cytokines, resulting in complete fistula healing. More recently, MSC-derived extracellular vesicles (EVs) have shown promising results in promoting fistula healing, particularly in cases of refractory or relapsing fistulas. Notably, the activation of macroautophagy (hereafter referred to as autophagy) in MSCs has been shown to accelerate the healing process. This narrative review discusses the mechanisms underlying PFCD pathogenesis, the therapeutic roles of MSCs and their EVs, and the potential role of autophagy upregulation in enhancing MSC function and EV production.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansRectal FistulaCrohn DiseaseDisease Models, AnimalTreatment OutcomeMesenchymal Stem Cell TransplantationWound HealingAutophagy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research